Dabigatran Etexilate Mesylate
6 NDCs across 1 manufacturer|0 Generic,6 Brand
Dabigatran Etexilate Mesylate is used to treat pulmonary embolism and venous thrombosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Oct 19, 2010, and the first generic was approved Mar 11, 2020. FDA's Orange Book lists 26 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $199 million on Dabigatran Etexilate Mesylate across 782,000 claims for 247,000 beneficiaries.
Dabigatran Etexilate Mesylate is available as 6 NDCs from 1 manufacturer (0 generic, 6 brand), with NADAC prices from $3.16 to $3.17 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
6
0G / 6B
Manufacturers
1
competing in market
Price Spread
$3.16 – $3.17
per EA
7d Activity
avg -0.0% WoW · of 6 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing DABIGATRAN ETEXILATE MESYLATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
PRADAXA 110 MG CAPSULE | $3.1665 per EA | — |
PRADAXA 110 MG CAPSULE | $3.1665 per EA | — |
PRADAXA 150 MG CAPSULE | $3.1605 per EA | -0.04% |
PRADAXA 150 MG CAPSULE | $3.1605 per EA | -0.04% |
PRADAXA 75 MG CAPSULE | $3.1584 per EA | +0.03% |
PRADAXA 75 MG CAPSULE | $3.1584 per EA | +0.03% |
Frequently Asked Questions
What is Dabigatran Etexilate Mesylate used to treat?
Dabigatran Etexilate Mesylate is used to treat pulmonary embolism and venous thrombosis, per the National Library of Medicine's MED-RT classification.
When did Dabigatran Etexilate Mesylate become available as a generic?
FDA approved the first generic Dabigatran Etexilate Mesylate (ANDA) on Mar 11, 2020. The Orange Book currently lists 26 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Dabigatran Etexilate Mesylate?
In 2024, Medicare Part D spent $199 million on Dabigatran Etexilate Mesylate across 782,000 claims for 247,000 beneficiaries.
How many Dabigatran Etexilate Mesylate products are on the market?
The Dabigatran Etexilate Mesylate drug market contains 6 NDCs from 1 manufacturer — 0 generic and 6 brand products.
What is the price range for Dabigatran Etexilate Mesylate?
NADAC reference prices for Dabigatran Etexilate Mesylate range from $3.1584 to $3.1665 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Dabigatran Etexilate Mesylate?
1 manufacturer lists Dabigatran Etexilate Mesylate in NADAC. Ranked by number of NDCs, the largest are Boehringer Ingelheim Pharmaceuticals Inc. (6).
How has the price of Dabigatran Etexilate Mesylate changed recently?
Over the past 7 days, 2 Dabigatran Etexilate Mesylate NDCs rose and 2 fell, with a market-wide average change of -0.0%.